These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 29980491)

  • 1. Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival.
    Lee MM; MacKinlay A; Semira C; Schieber C; Jimeno Yepes AJ; Lee B; Wong R; Hettiarachchige CKH; Gunn N; Tie J; Wong HL; Skinner I; Jones IT; Keck J; Kosmider S; Tran B; Field K; Gibbs P
    Clin Colorectal Cancer; 2018 Sep; 17(3):e569-e577. PubMed ID: 29980491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of chemotherapy and operation in patients with colorectal neuroendocrine carcinoma.
    Wu Z; Yu D; Zhao S; Gao P; Song Y; Sun Y; Chen X; Wang Z
    J Surg Res; 2018 May; 225():54-67. PubMed ID: 29605035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of tumor deposits on the prognosis and chemotherapy efficacy in stage III colorectal cancer patients with different lymph node status: A retrospective cohort study in China.
    Li X; An B; Zhao Q; Qi J; Wang W; Zhang D; Li Z; Qin C
    Int J Surg; 2018 Aug; 56():188-194. PubMed ID: 29936197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic implications of primary tumor location on recurrence in early-stage colorectal cancer with no associated risk factors.
    Kang SI; Kim DW; Kwak Y; Lee HS; Kim MH; Kim MJ; Oh HK; Kang SB
    Int J Colorectal Dis; 2018 Jun; 33(6):719-726. PubMed ID: 29594445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
    Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article.
    Yang L; Ma Q; Yu YY; Wang C; Meng WJ; Adell G; Albertsson M; Arbman G; Jarlsfelt I; Peng ZH; Li Y; Zhou ZG; Sun XF
    Medicine (Baltimore); 2014 Dec; 93(28):e266. PubMed ID: 25526455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
    Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
    Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer.
    Ahmed S; Pahwa P; Le D; Chalchal H; Chandra-Kanthan S; Iqbal N; Fields A
    Clin Colorectal Cancer; 2018 Jun; 17(2):e201-e206. PubMed ID: 29221688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
    Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
    BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
    Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
    J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced Mucinous Colorectal Cancer: Epidemiology, Prognosis and Efficacy of Chemotherapeutic Treatment.
    Ott C; Gerken M; Hirsch D; Fest P; Fichtner-Feigl S; Munker S; Schnoy E; Stroszczynski C; Vogelhuber M; Herr W; Evert M; Reng M; Schlitt HJ; Klinkhammer-Schalke M; Teufel A
    Digestion; 2018; 98(3):143-152. PubMed ID: 29870979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Data for High-risk Stage II Colorectal Cancer - The Role of Tumor Side in the Adjuvant Setting.
    Araujo CS; Venchiarutti Moniz CM; Bonadio RC; Watarai GY; Rojas J; Nogueira PVS; Martinez JK; Moraes PMG; Braghiroli MI; Sabbaga J; Hoff PM
    Clin Colorectal Cancer; 2021 Jun; 20(2):e100-e108. PubMed ID: 33234431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor.
    Kumar R; Price TJ; Beeke C; Jain K; Patel G; Padbury R; Young GP; Roder D; Townsend A; Bishnoi S; Karapetis CS
    Clin Colorectal Cancer; 2014 Jun; 13(2):87-93. PubMed ID: 24373733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcome and Prognostic Factors of Sporadic Colorectal Cancer in Young Patients: A Large Institutional-Based Retrospective Study.
    Kim TJ; Kim ER; Hong SN; Chang DK; Kim YH
    Medicine (Baltimore); 2016 May; 95(19):e3641. PubMed ID: 27175682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.
    Midgley RS; McConkey CC; Johnstone EC; Dunn JA; Smith JL; Grumett SA; Julier P; Iveson C; Yanagisawa Y; Warren B; Langman MJ; Kerr DJ
    J Clin Oncol; 2010 Oct; 28(30):4575-80. PubMed ID: 20837956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
    Sun J; Ilich AI; Kim CA; Chu MP; Wong GG; Ghosh S; Danilak M; Mulder KE; Spratlin JL; Chambers CR; Sawyer MB
    Clin Colorectal Cancer; 2016 Sep; 15(3):257-63. PubMed ID: 26803708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.